2026-02-26 14:02Financial Data and Key Metrics Changes - Fourth quarter total revenue increased by 17% year-over-year to $127.6 million, driven by strong contributions from XACDURO and NUZYRA [20] - Full year revenues grew by 15% to $460.2 million, reflecting steady progress across the commercial portfolio [20] - Loss from operations improved by 19% for the full year to $229.4 million, with a 25% improvement when adjusted for non-cash expenses [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full year revenue growth of 15% year-over-year [6] - XACDURO performance reflected strong patient demand and expanding hospital adoption, although supply constraints limited full realization of demand [20] - VYVGART showed strong physician confidence and stable patient demand, with expectations for continued growth in 2026 [17] Market Data and Key Metrics Changes - The global oncology market presents a significant opportunity, with an estimated total addressable market exceeding $9 billion for Zoci in small cell lung cancer and neuroendocrine carcinomas [11] - The U.S. market for small cell lung cancer has approximately 15,000 patients available for second-line treatment and 25,000 for first-line treatment [61] Company Strategy and Development Direction - The company aims to build a globally competitive pipeline, focusing on execution and preparation for multiple growth opportunities in 2026 [5][19] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies in oncology [17] - The company is leveraging its presence in China to access a fast-evolving innovation ecosystem, enhancing its global and regional pipeline [8] Management's Comments on Operating Environment and Future Outlook - Management highlighted a challenging macro and operating environment but expressed confidence in the stability provided by the China business [6] - The focus for 2026 is on maintaining the strength of the existing business while preparing for multiple growth opportunities, including the launch of KarXT and advancing late-stage assets [19] - Management emphasized the importance of disciplined spending and maintaining a strong cash position to support future growth [21] Other Important Information - The company has a strong cash position, ending the quarter with $790 million, which positions it well for executing its priorities [21] - The company is focused on expanding its global pipeline while preserving financial flexibility for future investments [46] Q&A Session Summary Question: Can you provide any color on how we should be thinking about revenues and expenses for 2026? - Management expects good growth opportunities for VYVGART and ZEJULA, with modest investments required to support launches [24] Question: Can you remind us of the implications of the intracranial activity in patients with brain mets for Zoci? - Zoci has shown an 80% response rate in patients with untreated brain metastases, which is a significant advantage [29] Question: Can you elaborate on the U.S., China development model? - The company is applying its efficient development structure in China to global trials, allowing for faster and higher quality execution [34] Question: What should we expect from KarXT in 2026 and 2027? - The commercial launch of KarXT is expected in the second quarter of 2026, with a focus on building disease awareness and establishing clinical confidence [73] Question: What is the expectation for completion of enrollment for Zoci? - Enrollment is expected to be completed by the end of the first quarter of next year, with a goal for accelerated approval in 2028 [48]